Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Exploratory analysis of variant allele frequency and progression-free survival
    Meeting Abstract

    Cloughesy, T.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Peters, K.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, multicenter, double blind, phase 2B study of Igv-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients
    Meeting Abstract

    Lee, I.; Judy, K.; Schulder, M.; Hanft, S.; Evans, L.; Wu, J.; Aulakh, S.; Wong, E.; Agarwal, V.; Ramakrishna, R.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide plus radiotherapy in adults with recurrent or newly diagnosed glioblastoma
    Meeting Abstract

    Roth, P.; Papadopoulos, K. P.; Vieito, M.; Yang, J.; Majd, N.; Sepúlveda, J.; Schaff, L.; Moreno, V.; Pérez-Larraya, J. G.; Micallef, S.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Doz, F.; Geoerger, B.; Italiano, A.; Lassen, U.; Nilsson, A.; Nysom, K.; Spano, J. P.; Norenberg, R.; Bernard-Gauthier, V.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of erdafitinib in patients with high-grade and low-grade gliomas and prespecified fibroblast growth factor receptor alterations (FGFRALT) in the Ragnar trial
    Meeting Abstract

    Reardon, D.; Welsh, L.; Shih, K.; Shimizu, T.; Goeminne, J. C.; Geoerger, B.; Baldini, C.; Massard, C.; Loriot, Y.; Pant, S.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
    Meeting Abstract

    Venneti, S.; Kawakibi, A. R.; Ji, S.; Waszak, S.; Sweha, S.; Mota, M.; Pun, M.; Deogharkar, A.; Chung, C.; Tarapore, R.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A case of widespread extracranial metastases from a gliosarcoma
    Meeting Abstract

    Mohamadpour, M.; Budhu, J.
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Brain tumors in United States military veterans
    Meeting Abstract

    Waite, K.; Bihn, J.; Cioffi, G.; Neff, C.; Kruchko, C.; Ostrom, Q.; Swinnerton, K.; Elbers, D.; Mooney, M. A.; Rachlin, J.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of BRAF inhibitor plixorafenib (Fore8394) in recurrent, primary central nervous system tumors (PCNST)
    Meeting Abstract

    de la Fuente, M.; Butowski, N.; Taylor, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Allen, C.; Ammakkanavar, N.; Michelson, G.; Jiang, P.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 safety lead-in and randomized open-label perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1-mutant astrocytomas: Safety lead-in results
    Meeting Abstract

    Wen, P.; Peters, K.; de la Fuente, M.; Mellinghoff, I.; Arrillaga-Romany, I.; Kumthekar, P.; Clarke, J.; Puduvalli, V.; de Groot, J.; Zhang, X. M.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save